Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

Leqselvi is a medicine used to treat severe alopecia areata, manufactured by Sun Pharmaceutical. The generic name of the drug ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma wins US court case, lifting restrictions on launching LEQSELVI, a drug for autoimmune disorder causing hair loss.

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Delhi: In a major relief to Sun Pharmaceutical Industries Ltd, the U.S. Court of Appeals for the Federal Circuit has vacated ...

Sun Pharma shares gained after a U.S. court lifted an injunction, clearing the way for the launch of LEQSELVI, its drug for ...